发明授权
US07718776B2 Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
有权
人抗OPGL中和抗体作为选择性OPGL途径抑制剂
- 专利标题: Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
- 专利标题(中): 人抗OPGL中和抗体作为选择性OPGL途径抑制剂
-
申请号: US10408901申请日: 2003-04-07
-
公开(公告)号: US07718776B2公开(公告)日: 2010-05-18
- 发明人: William J. Boyle , Eugene Medlock , John J. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- 申请人: William J. Boyle , Eugene Medlock , John J. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- 申请人地址: US CA Thousand Oaks US NJ Princeton
- 专利权人: Amgen Inc.,Medarex, Inc.
- 当前专利权人: Amgen Inc.,Medarex, Inc.
- 当前专利权人地址: US CA Thousand Oaks US NJ Princeton
- 代理机构: McDonnell Boehnen Hulbert & Berghoff LLP
- 主分类号: C12P21/08
- IPC分类号: C12P21/08 ; C07K16/00 ; C12P21/04 ; A61K39/395
摘要:
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
公开/授权文献
信息查询